Dates
February 21-22, 2019
International Convention Center
Jerusalem, Israel
Contact Us
imsregional2019@kenes-events.com


Welcome to the First Regional International Myeloma Meeting in Jerusalem

It is my pleasure and honor to invite and host you in Jerusalem, the holy city, for the First Regional International Myeloma Meeting,
which will take place on February 21-22, 2019.

The International Myeloma Society (IMS), the Israel Society of Hematology and Transfusion Medicine and The Israel Myeloma Working Group have collaborated in launching this new initiative. Top world-known myeloma physicians and investigators, coming from all parts of the globe, will assure high scientific standards and extremely attractive program. Various topics on all relevant aspects of multiple myeloma will be covered, including the genetic basis of the disease, pathogenesis, diagnostic workup, clinical manifestations and complications, treatment strategies and follow up methods.
The excellent scientific program will combine educational sessions with cutting-edge update information, as well as real-world patients discussion, thus, all people involved in the field will find it interesting, educative, updating and stimulating.

The Kenes Company, with its international reputation and experience will assure a perfect logistic organization together with superb social and cultural program and tours, which can take place only in a city such as Jerusalem

So register now and come to Jerusalem: You will have a unique opportunity to combine highly myeloma scientific conference, meetings with colleagues and world-known key opinion leaders and a stimulating trip to the holy city – all these in the special atmosphere of Jerusalem.

Moshe Mittelman   

President, Israel Society of Hematology

and Transfusion Medicine

Chairman, Organizing Committee

 

 Moshe Gatt

Chairman, Israel Myeloma Working Group


About Israel Society Of Hematology And Transfusion Medicine

Donec a rhoncus nulla. Fusce sit amet commodo enim. Duis elit metus, volutpat vel pretium vel, aliquam a lectus. Phasellus luctus rutrum erat, sit amet pellentesque sem tincidunt sed. Proin vel enim viverra, volutpat velit ut, condimentum metus. In sapien purus, vehicula sollicitudin pharetra at, fringilla quis felis. Nam vel accumsan nisi, eu ultrices risus. Duis tincidunt lorem odio, ac laoreet libero venenatis eget. Maecenas vel iaculis nulla. Nullam et luctus lectus. Sed dignissim sapien in dapibus vestibulum. Nulla cursus lobortis metus, in vulputate urna rhoncus id. Proin convallis erat id erat rutrum feugiat.

 

Quisque cursus eu mi ut semper. Nullam vestibulum mauris dui, eget semper ex hendrerit sed. Etiam justo libero, commodo nec ultricies at, cursus sit amet diam. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus scelerisque, lacus ut euismod mollis, magna mauris fringilla mi, ut lacinia lacus lectus tempus mauris. Proin elit quam, hendrerit eu vehicula et, tempus ac enim. Proin et feugiat arcu. Sed venenatis mollis sodales. Cras eros justo, tincidunt quis urna non, venenatis efficitur ex. Praesent ultrices libero elit, vel accumsan arcu accumsan eget. Vivamus sodales nisl eu vestibulum placerat. Phasellus at nibh orci. Nunc non augue sit amet nunc blandit dapibus.

Meeting Topics

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit
  • Quisque non nunc id nulla eleifend auctor
  • In consequat arcu in tellus porta, commodo sagittis sapien interdum
  • Praesent fringilla quam at velit mattis, non venenatis justo ullamcorper
  • Aliquam non lorem mattis, vestibulum felis non, auctor mauris
  • Etiam in mauris vel dui cursus consequat
  • Sed sed velit semper, volutpat magna non, consectetur enim

Meet the Speakers

Dr. Artur Jurczyszyn

Dr. Artur Jurczyszyn

Dr. Artur Jurczyszyn

Specialist in internal medicine and hematology, assistant professor at the Department of Hematology, Jagiellonian University Medical College, head of Department of Heamatology University Hospital In Kraków. His present clinical and research activities center around the

treatment of plasma cell dyscrasia. Author of more than 130 research paperswith cumulative Impact Factor >250; Hirsch Index 13; scientific editor of six monographs on clinical hematology. Member of the Board at the Polish Myeloma Working Group affiliated by the Polish Society of Hematology and Transfusion Medicine, International Myeloma Working Group (IMWG), International Myeloma Society (IMS), European Hematology Association (EHA), and American Society of Hematology (ASH).

In 1996, graduated from the Faculty of Medicine, Jagiellonian University. In 2003, awarded with the doctor’s degree for his research on the role of cytokines in pathogenesis of multiple myeloma. In 2016, awarded with the title of associate professor in medicine for the cycle of publications about the biology and treatment of plasma cell myeloma. Described the largest groups of patients with a rare cutaneous form of multiple myeloma (53 patients) and central nervous system involvement by multiple myeloma (172 patients). Author of clinical reports presenting 101 patients with secondary plasma cell leukemia and 52 patients who developed multiple myeloma before 30 years of age.

Completed internships at John Theurer Cancer Institute in Hackensack (2012), and Dana Farber Cancer Institute in Boston (2014). In 2015, granted a 650th Anniversary Medal of the Jagiellonian University, for his long-year clinical and research service. Co-founder and president of the Myeloma Treatment Foundation Center, a registered charity established in 2008. In 2016, granted „Amicus Hominum” award from Małopolska Provincial Office, for individuals acting for the other’s good in the field of health promotion and health protection.

In 2017, received the first-degree award for research achievements from the Minister of Health and Higher Education. In 2018, presented with Tadeusz Browicz award from the Polish Academy of Arts and Sciences for the development of an original prognostic index in primary plasma cell leukemia. Since 2017, Chairmen at the Cracow Branch of the Polish Society of Hematology and Transfusion Medicine.

Dean’s Proxy at the Faculty of Medicine, Jagiellonian University Medical College.

 

Dr. Irene Ghobrial

Dr. Irene Ghobrial

Dr. Irene Ghobrial

Dr. Irene Ghobrial is an Associate Professor at Dana-Farber Cancer Institute (DFCI), Harvard Medical School, Boston, MA and an Associate member of the Broad Institute, Cambridge, MA. She is the Director of the Clinical Investigator research program at Dana-Farber Cancer Institute, co-director of the Center for Prevention of Progression (CPOP) and co-leader of the Blood Cancer Research Partnership (BCRP). She is also the director of the Michele & Stephen Kirsch Laboratory.

She received her medical degree from Cairo University School of Medicine, Egypt. She completed her internal medicine training at Wayne State University, MI, and her Hematology/Oncology subspecialty training at Mayo Clinic College of Medicine, MN.

Her research focuses on understanding mechanisms of tumor progression from early precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and Smoldering disease to symptomatic Multiple Myeloma (MM) and Waldenstrom Macroglobulinemia (WM). She specifically focuses on the role of the malignant bone marrow niche in regulating disease progression. She is interested in the development of new molecular/genomic markers that predict progression in precursor conditions which can identify patients who should be eligible for therapeutic interventions to prevent progression or potentially cure the disease at the early stages of the disease before clonal evolution occurs.

She authored or co-authored over 250 publications and book chapters and has received funding support from the National Cancer Institute as well as multiple foundations including Stand Up-to Cancer, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation and International Myeloma Foundation. She has received multiple awards including the Ken Anderson Young Investigator Award, Robert A. Kyle Award for Research in Waldenstrom Macroglobulinemia, and Mentor of the Year Award at DFCI.

Dr. Paul Richardson

Dr. Paul Richardson

Dr. Paul Richardson

After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology from 1994 onwards at Dana-Farber Cancer Institute (DFCI), Dr. Paul Richardson joined the Jerome Lipper Myeloma Center in 1999, was appointed Clinical Director in 2001, and led the development of several first-generation novel drugs including bortezomib, lenalidomide and pomalidomide. Subsequent studies have focused on next generation novel drugs including histone deacetylase inhibitors such as panobinostat and other small molecules including the second-generation proteasome inhibitors NPI 0052 (also known as marizomib) and MLN 9708 (now known as ixazomib), with the goal of further improving patient outcome. More recently, his clinical innovations have been in the development of the breakthrough monoclonal antibodies elotuzumab and daratumumab for the treatment of both untreated and relapsed myeloma.
Previously, his senior investigator role in the VISTA trial comparing bortezomib in combination with melphalan and prednisone versus melphalan and prednisone alone as part of an international Phase 3 trial established bortezomib, melphalan and prednisone (VMP) as a new treatment standard in patients not eligible for stem cell transplant. At present, his major effort has been focused on the Intergroup Francophone Myelome (IFM)/DFCI clinical trial in newly diagnosed patients eligible for stem cell transplant treated with lenalidomide, bortezomib and dexamethasone (so-called RVD). This regimen has generated an unprecedented response rate, leading to its adoption in this international study (as well as in the United States and elsewhere), which incorporates genomic and proteomic evaluation to establish a future platform for tailored therapy.
Other important contributions include the management of treatment-emergent neuropathy in myeloma. Similarly, the development of defibrotide for the treatment and prevention of hepatic veno-occlusive disease following stem cell transplantation has been aimed at improving therapeutic outcome, with defibrotide emerging as the first agent approved for this unmet medical need.
He has published extensively, having authored or co-authored over 360 original articles and 280 reviews, chapters, and editorials in peer-reviewed journals. In addition to holding positions on the Editorial Boards of leading journals, he is prior Chairman of the Multiple Myeloma Research Consortium (MMRC), Clinical Trials Core, a position held for 5 years as part of a rotating tenure, and for which he continues as a member of the Steering and Project Review Committee. He was also a member of ASCO Hematologic Malignancies Subcommittee for the required one-year term, and then for one year on the ASCO Internet Cancer Information Committee during 2017. He was appointed Chair of the Alliance Myeloma Committee in 2011 and continues in this role.
Honors include the George Canellos Award for Excellence in Clinical Research and Patient Care, and The Tisch Outstanding Achievement Award for Clinical Research, as well an honorary Fellowship of the Royal College of Physicians (UK), given in recognition for international contributions in multiple myeloma and stem cell transplantation. He was a co-recipient of the prestigious Warren Alpert Foundation Prize in recognition of the successful therapeutic targeting of the ubiquitin-proteasome pathway. He was also a co-recipient of the Accelerator Award for contributions to clinical research and patient enrollment in MMRC studies, as well as for the Research Center of the Year Award in 2009, followed by a second award for Center of the Year in 2017. He was ranked by Thomson Reuters Science Watch amongst the top 19 investigators at DFCI for the most highly cited research in 2016. Most recently, he was the co-recipient of the ASH Ernest Beutler Prize for clinical science and translational research in the development of proteasome inhibition as an effective treatment strategy for multiple myeloma in 2015; the COMY Award for MM research (Paris, France) in 2016, and the IMF Robert A. Kyle Lifetime Achievement Award in 2017.

Dr. Meletios A. Dimopoulos

Dr. Meletios A. Dimopoulos

Dr. Meletios A. Dimopoulos

Dr. Meletios A. Dimopoulos, MD is Professor and Chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, Athens, Greece. He has been elected Vice Dean of the Medical School for the academic years 2007-2011 and Dean for the academic years 2011-2015. In February 2015 he was elected Rector of the National and Kapodistrian University of Athens for a 4 year term.  He obtained his medical degree from the National and Kapodistrian University of Athens in 1985, completed a residency in internal medicine at the Royal Victoria Hospital, McGill University, Montreal, Canada and a fellowship in hematology/oncology at the University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

Dr. Dimopoulos is a member of numerous scientific societies and has authored more than 931 publications (November 2018) in peer-reviewed journals, as well as numerous abstracts and several textbook chapters primarily focusing on plasma cell dyscrasias and genitourinary and gynecologic cancers. He has more than 53000 citations and his h-index is 108 (Scopus) and more than 44000 citations and an h-index 100 (ISI).  He is a journal reviewer for several journals including New England Journal of Medicine, Blood, Journal of Clinical Oncology, Haematologica, Leukemia, Cancer, European Journal of Haematology, Leukemia and Lymphoma etc. Dr. Dimopoulos was Associate Editor of the European Journal of Internal Medicine (2001-2007), is an Associate Editor of Current Hematologic Malignancy Reports and is an Editorial Board Member of the Journal of Clinical Oncology (2005-2008), of Haematologica, of Leukemia and Lymphoma, of Clinical Lymphoma, Myeloma and Leukemia (2018), of Expert Review of Hematology and of Blood Advances. Dr. Dimopoulos was an elected member of the Board of the International Myeloma Society (2013-2017).

Dr. Dimopoulos serves on the Scientific Advisory Boards of the International Myeloma Foundation, of the International Waldenstrom’s Macroglobulinemia Foundation and he is a member of the Board of the European Myeloma Network. Dr. Dimopoulos organized the XIth International Myeloma Workshop and the IVrth International Workshop on Waldenstrom’s Macroglobulinemia (Kos Island, Greece June 2007). In March 2013 Dr. Dimopoulos was elected as a member of the Board of the International Myeloma Society. Currently he is the chairman of the Greek Myeloma Study Group and of the Balkan Myeloma Study Group.

He is a recipient of the Robert A. Kyle Award for outstanding contributions to Waldenstrom’s macroglobulinemia (May 2003), a recipient of Waldenstrom’s award for Myeloma Research of the International Myeloma Society (March 2017), recipient of the CoMy Excellence Award (May 2017). In August 2017 he was given the title “Officier dans l’ Ordre des Palmes academiques” (Republique Francaise, Ministere de l’ Education Nationale). In May 2018 he was elected as membre associe etranger of the National Academy of Medecine of France.

Currently he is the Chairman of the Board of the Foundation of “Julia and Alexander N. Diomedes Botanic Garden” and he is a member of the Board of the National Greek Committee for UNESCO.

Dr. Kenneth Anderson

Dr. Kenneth Anderson

Dr. Kenneth Anderson

Kenneth Anderson, MD is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor.

 

Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma.  He has developed laboratory and animal models of the tumor in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies.  His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome. He is a recipient of many scientific and humanitarian awards including: the International Myeloma Workshop Waldenstrom’s Award; the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award; the American Association for Cancer Research Joseph H. Burchenal Award; the American Society of Hematology William Dameshek Prize; the Johns Hopkins Society of Scholars; election to the Royal Colleges of Physicians and of Pathologists of the United Kingdom; the American Society of Clinical Oncology David A. Karnofsky Award; the Hope Funds for Cancer Research Award of Excellence in Clinical Research; the Ron Burton Humanitarian Award; the Harvard Medical School Warren Alpert Foundation Prize; the American Cancer Society Medal of Honor in Science, the Leonard P. Zakim Patient Advocacy Award: the Samuel Waxman Research Foundation David Workman Memorial Award; the University of Miami Sylvester Cancer Center Annual Zubrod Memorial Award; and appointment as a Fellow of the American Association for Cancer Research Academy, to the Board of Scientific Advisors of the National Cancer Institute, and to the Institute of Medicine’s National Cancer Policy Forum.  He is a member of the Institute of Medicine of the National Academy of Sciences, served as President of the International Myeloma Society, and as President of the American Society of Hematology in 2017.

 

Dr. Anderson is a graduate of Boston University and Johns Hopkins Medical School. He trained in internal medicine at Johns Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at Dana-Farber Cancer Institute.

 

Dr. Jesús San Miguel

Dr. Jesús San Miguel

Dr. Jesús San Miguel

Dr. Jesus San-Miguel is Professor of Medicine (Haematology), Director of Clinical and Translational Medicine at the University of Navarra and he has served as director of the Hematology Department of the University Hospital of Salamanca for over 22 years (1991-2013).

His interest for multiple myeloma started with the PhD thesis in the early 80´ and since then he has devoted most part of his work to improve our understanding in the biology, prognosis and therapeutics of this disease. He has published over 775 papers in the most relevant journals: Blood, JCO, NEJM, Lancet Oncology, etc.

Prof. San Miguel is President of the International Myeloma Society, member of the Academy of Pharmacy of Castilla-León and the Royal Academy of Medicine of Salamanca, as well as member of the Advisory Board of the International Myeloma Foundation, the Multiple Myeloma Research Foundation, Carreras Foundation. He has served at the board of the Spanish Hematology Association, European Hematology Association and Genome Foundations. Among others is Associate Editor of Blood and he also was Associated Editor of Haematologica. He has received numerous prizes including the Michaeli Award for his contribution to Myeloma, the Waldenström Award, the Kyle life Achievement Award, the EHA “Jose Carreras” Award, the Rey Jaime I on Medical Research Award and the Spanish prizes on both Oncology and Translational Research.

Sponsors